Volume 5, Issue 2 (Journal of Clinical and Basic Research (JCBR) 2021)
jcbr 2021, 5(2): 26-41 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mohebbi A, Mirarab A, Shaddel R, Shafaei Fallah M, Memarian A. Molecular Dynamic Simulation and Docking of Cyclophilin A Mutants with its Potential Inhibitors. jcbr 2021; 5 (2) :26-41
URL: http://jcbr.goums.ac.ir/article-1-316-en.html
URL: http://jcbr.goums.ac.ir/article-1-316-en.html
1- Stem Cell Research Center, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
2- Department of Microbiology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
3- Student Research Committee, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
4- Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran , alimemarian@goums.ac.ir
2- Department of Microbiology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
3- Student Research Committee, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
4- Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran , alimemarian@goums.ac.ir
Abstract: (3652 Views)
Background and objectives: Cyclophilin A (CypA) is involved in various human biological processes. Its role in many pathological conditions makes it a promising target for treating human diseases, such as viral infections. The aim of the present study was to investigate docking of CypA mutants with its potential inhibitors using molecular dynamic simulation ((MDS).
Methods: The crystallographic structure of CypA was extracted from the protein database (PDB). Important CypA substitutions were obtained from the literature. CypA inhibitors were taken from chemical databases. The affinity and binding sites of the compounds to CypA and its mutants were also scaled through Autodock Vina. Root-mean-square deviation (RMSD), radios gyration, Lenard-jones potential, and hydrogen bonding were investigated by using MDS for 600 ps.
Results: The findings revealed that SangfA and HBF-0259 had more affinity to the CypA (-7.8Kcal/mol and -7.5Kcal/mol, respectively). Conformational changes were observed in CypA W121A/F mutants. SangfA complexed with CypA and its mutants had relatively stable RMSD. Higher Lenard-Jones potential has been observed in the interaction of SangfA to W121A, HBF-0259 to M61, and SCY-635 to H70F. The SangfA had a higher HBs ratio with CypA.
Conclusion: Given the higher affinity of SangfA and HBF-0259 to CypA and its mutants, they would influence the stability of the protein. RMSD analysis revealed that SangfA is probably ligated to CypA and its mutants, which are relatively stable. Substitution at W121 residue would reduce inhibitor binding to CypA.
Methods: The crystallographic structure of CypA was extracted from the protein database (PDB). Important CypA substitutions were obtained from the literature. CypA inhibitors were taken from chemical databases. The affinity and binding sites of the compounds to CypA and its mutants were also scaled through Autodock Vina. Root-mean-square deviation (RMSD), radios gyration, Lenard-jones potential, and hydrogen bonding were investigated by using MDS for 600 ps.
Results: The findings revealed that SangfA and HBF-0259 had more affinity to the CypA (-7.8Kcal/mol and -7.5Kcal/mol, respectively). Conformational changes were observed in CypA W121A/F mutants. SangfA complexed with CypA and its mutants had relatively stable RMSD. Higher Lenard-Jones potential has been observed in the interaction of SangfA to W121A, HBF-0259 to M61, and SCY-635 to H70F. The SangfA had a higher HBs ratio with CypA.
Conclusion: Given the higher affinity of SangfA and HBF-0259 to CypA and its mutants, they would influence the stability of the protein. RMSD analysis revealed that SangfA is probably ligated to CypA and its mutants, which are relatively stable. Substitution at W121 residue would reduce inhibitor binding to CypA.
Article Type: Research |
Subject:
Basic medical sciences
References
1. Piotukh K, Gu W, Kofler M, Labudde D, Helms V, Freund C. Cyclophilin A binds to linear peptide motifs containing a consensus that is present in many human proteins. J Biol Chem. 2005;280(25):23668-74. [View at Publisher] [DOI] [PubMed] [Google Scholar]
2. Zydowsky LD, Etzkorn FA, Chang HY, Ferguson SB, Stolz LA, Ho SI, et al. Active site mutants of human cyclophilin A separate peptidyl‐prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition. Protein Sci. 1992;1(9):1092-9. [View at Publisher] [DOI] [PubMed] [Google Scholar]
3. Nigro P, Pompilio G, Capogrossi MC. Cyclophilin A: A key player for human disease. Cell Death Dis. 2013;4(10). [View at Publisher] [DOI] [PubMed] [Google Scholar]
4. Hopkins S, Dimassimo B, Rusnak P, Heuman D, Lalezari J, Sluder A, et al. The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection. J Hepatol. 2012;57(1):47-54. [View at Publisher] [DOI] [PubMed] [Google Scholar]
5. Hopkins S, Bobardt M, Chatterji U, Garcia-Rivera JA, Lim P, Gallay PA. The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin a complexes. Antimicrob
Agents Chemother. 2012;56(7):3888-97. [View at Publisher] [DOI] [PubMed] [Google Scholar]
6. Hopkins S, Scorneaux B, Huang Z, Murray MG, Wring S, Smitley C, et al. SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of Hepatitis C virus RNA replication in vitro. Antimicrob Agents Chemother. 2010;54(2):660-72. [View at Publisher] [DOI] [PubMed] [Google Scholar]
7. Ahmed-Belkacem A, Colliandre L, Ahnou N, Nevers Q, Gelin M, Bessin Y, et al. Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities. Nat Commun. 2016;7. [View at Publisher] [DOI] [PubMed] [Google Scholar]
8. Naoumov N V. Cyclophilin inhibition as potential therapy for liver diseases. J Hepatol. 2014;61(5):1166-74. [View at Publisher] [DOI] [PubMed] [Google Scholar]
9. Mohebbi A, Mohammadi S, Memarian A. Prediction of HBF-0259 interactions with hepatitis B Virus receptors and surface antigen secretory factors. VirusDisease. 2016;27(3):234-41. [View at Publisher] [DOI] [PubMed] [Google Scholar]
10. Śledź P, Caflisch A. Protein structure-based drug design: from docking to molecular dynamics. Curr Opin Struct Biol. 2018;48:93-102. [View at Publisher] [DOI] [PubMed] [Google Scholar]
11. Lv M, Shi T, Mao X, Li X, Chen Y, Zhu J, et al. 1-(2,6-Dibenzyloxybenzoyl)-3-(9H-fluoren-9-yl)-urea: A novel cyclophilin A allosteric activator. Biochem Biophys Res Commun. 2012;425(4):938-43. [View at Publisher] [DOI] [PubMed] [Google Scholar]
12. Ivery MTG. A proposed molecular model for the interaction of calcineurin with the cyclosporin A-Cyclophilin a complex. Bioorganic Med Chem. 1999;7(7):1389-402. [View at Publisher] [DOI] [PubMed] [Google Scholar]
13. Berman HM, Battistuz T, Bhat TN, Bluhm WF, Bourne PE, Burkhardt K, et al. The protein data bank. Acta Crystallogr Sect D Biol Crystallogr. 2002;58(6 I):899-907. [View at Publisher] [DOI] [PubMed] [Google Scholar]
14. Kallen J, Mikol V, Taylor P, D.walkinshaw M. X-ray structures and analysis of 11 cyclosporin derivatives complexed with cyclophilin A. J Mol Biol. 1998;283(2):435-49. [View at Publisher] [DOI] [PubMed] [Google Scholar]
15. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera - A visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605-12. [View at Publisher] [DOI] [PubMed] [Google Scholar]
16. Bolton EE, Wang Y, Thiessen PA, Bryant SH. Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities. Annu Rep Comput Chem. 2008;4:217-41. [View at Publisher] [DOI] [Google Scholar]
17. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis. 1997;18(15):2714-23. [View at Publisher] [DOI] [PubMed] [Google Scholar]
18. Chase F, Avenue B. Rotamer libraries in the 21 st century Roland L Dunbrack Jr. Proteins [Internet]. 2002;12(4):431-40. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0959440X02003445 [View at Publisher] [DOI] [Google Scholar]
19. Najmanovich R, Kuttner J, Sobolev V, Edelman M. Side-chain flexibility in proteins upon ligand binding. Proteins Struct Funct Genet. 2000;39(3):261-8.
https://doi.org/10.1002/(SICI)1097-0134(20000515)39:3<261::AID-PROT90>3.0.CO;2-4 [View at Publisher] [DOI] [PubMed] [Google Scholar]
20. Liu J, Chen CM, Walsh CT. Human and Escherichia coli Cyclophilins: Sensitivity to Inhibition by the Immunosuppressant Cyclosporin A Correlates with a Specific Tryptophan Residue. Biochemistry. 1991;30(9):2306-10. [View at Publisher] [DOI] [PubMed] [Google Scholar]
21. Allouche A. Software News and Updates Gabedit - A Graphical User Interface for Computational Chemistry Softwares. J Comput Chem. 2012;32:174-82. [View at Publisher] [DOI] [PubMed] [Google Scholar]
22. Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, et al. Gromacs: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1-2:19-25. [View at Publisher] [DOI] [Google Scholar]
23. Oostenbrink C, Villa A, Mark AE, Van Gunsteren WF. A biomolecular force field based on the free enthalpy of hydration and solvation: The GROMOS force-field parameter sets 53A5 and 53A6. J Comput Chem. 2004;25(13):1656-76. [View at Publisher] [DOI] [PubMed] [Google Scholar]
24. Schüttelkopf AW, Van Aalten DMF. PRODRG: A tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr Sect D Biol Crystallogr. 2004;60(8):1355-63. [View at Publisher] [DOI] [PubMed] [Google Scholar]
25. Ihaka R, Gentleman R. R: A Language for Data Analysis and Graphics. J Comput Graph Stat. 1996;5(3):299-314. [View at Publisher] [DOI] [Google Scholar]
26. jIhaka R, Gentleman R. R: A Language for Data Analysis and Graphics. J Comput Graph Stat. 1996;5(3):299-314. [View at Publisher] [DOI] [Google Scholar]
27. McGowan LC, Hamelberg D. Conformational plasticity of an enzyme during catalysis: Intricate coupling between cyclophilin a dynamics and substrate turnover. Biophys J. 2013;104(1):216-26. [View at Publisher] [DOI] [PubMed] [Google Scholar]
28. Sargsyan K, Grauffel C, Lim C. How Molecular Size Impacts RMSD Applications in Molecular Dynamics Simulations. J Chem Theory Comput. 2017;13(4):1518-24. [View at Publisher] [DOI] [PubMed] [Google Scholar]
29. Dietrich L, Ehrlich LS, LaGrassa TJ, Ebbets-Reed D, Carter C. Structural Consequences of Cyclophilin A Binding on Maturational Refolding in Human Immunodeficiency Virus Type 1 Capsid Protein. J Virol. 2001;75(10):4721-33. [View at Publisher] [DOI] [PubMed] [Google Scholar]
30. Lammers M, Neumann H, Chin JW, James LC. Acetylation regulates Cyclophilin A catalysis, immunosuppression and HIV isomerization. Nat Chem Biol. 2010;6(5):331-7. [View at Publisher] [DOI] [PubMed] [Google Scholar]
31. Chatterji U, Bobardt M, Selvarajah S, Yang F, Tang H, Sakamoto N, et al. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J Biol Chem. 2009;284(25):16998-7005. [View at Publisher] [DOI] [PubMed] [Google Scholar]
32. Ciccone DS, Natelson BH. Comorbid illness in women with chronic fatigue syndrome: A test of the single syndrome hypothesis. Psychosom Med. 2003;65(2):268-75. [View at Publisher] [DOI] [PubMed] [Google Scholar]
33. Hamelberg D, Mecammon JA. Mechanistic insight into the role of transition-state stabilization in cyclophilin A. J Am Chem Soc. 2009;131(1):147-52. [View at Publisher] [DOI] [PubMed] [Google Scholar]
34. Ladani ST, Hamelberg D. Entropic and surprisingly small intramolecular polarization effects in the mechanism of cyclophilin A. J Phys Chem B. 2012;116(35):10771-8. [View at Publisher] [DOI] [PubMed] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0).